<DOC>
	<DOCNO>NCT01244321</DOCNO>
	<brief_summary>The objective control , non-randomized , single-center pilot study ( CoSeal arm prospective ) study evaluate efficacy synthetic surgical hydrogel CoSeal® prevention cardiac adhesion formation patient submit VAD procedure .</brief_summary>
	<brief_title>COVADIS Pilot Trial : COseal Ventricular Assist DevIceS</brief_title>
	<detailed_description>In past decade use ventricular assist device ) ( VADs ) bridge heart transplantation ( HTx ) , case , recovery ventricular function increase , time , duration implantation period lengthen dramatically . When remove VADs long period , surgeon face severe pericardial adhesion mediastinum level surround tissue due inflammatory response . During resternotomy , dissection adhesion increase surgical time source lesion cardiac vascular structure severe bleed moment transplantation device remove . Many product use prevent reduce adhesion ideal antiadhesive treatment remain elusive . CoSeal® , license synthetic hydrogel ( Baxter , USA ) show reduce pericardial adhesion limited series reoperations .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<criteria>Inclusion criterion ( CoSeal group ) : 1 . Written inform consent obtain subject prior participation study 2 . At least 18 year age 3 . Subjects indication LVAD implantation , meeting requirement LVAD implantation . Patients investigator anticipates LVAD removal earlier 6 week LVAD implantation . Inclusion criterion ( CoSeal control group ) : 1 . Written inform consent obtain subject prior participation study 2 . At least 18 year age 3 . Subjects LVAD 6 week . Exclusion criterion ( CoSeal group ) : 1 . Concomitant use antiadhesion product 2 . Immune system disorder , immunodeficiency immunosuppression 3 . Known hypersensitivity component study product 4 . Patients concurrently participate another clinical trial adhesion prevention seal evaluation receive investigational drug device within previous 30 day 5 . Patients previously subject another LVAD implantation/explantation 6 . Pregnant breastfeed woman . Exclusion criterion ( Co Seal control group ) : 1 . Known use antiadhesion product VAD implantation 2 . Immune system disorder , immunodeficiency immunosuppression 3 . Patients concurrently participate another clinical trial adhesion prevention seal evaluation receive investigational drug device within previous 30 day 4 . Patients previously subject another LVAD implantation/explantation 5 . Pregnant breastfeed woman .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>End stage heart failure</keyword>
	<keyword>heart transplantation</keyword>
	<keyword>Ventricular assist device</keyword>
	<keyword>Patients end stage heart failure</keyword>
	<keyword>await heart transplantation</keyword>
</DOC>